SAM #OC-2026-135667

FDA Sole Source Contract for BDBV Sequencing and Bioanalytical Research

This notice announces the FDA's intent to award a sole source contract to The University of Liverpool for specialized research services related to Bundibugyo virus disease (BDBV) in the 2026 outbreak. - Agency: Food and Drug Administration (FDA), Department of Health and Human Services - Procurement Type: Sole source, firm-fixed price purchase order - Vendor: The University of Liverpool - NAICS Code: 541714 (Research and Development in Biotechnology, except Nanobiotechnology) - Scope of Work: - Sequencing Bundibugyo virus disease (BDBV) during the 2026 outbreak - Acquisition of critical reagents, reference standards, and internal standards - Support for bioanalytical method development and sample analysis - Quantification of CYP enzyme substrates/metabolites and transporter substrates in hepatocyte experiments - Unique Requirements: - Specialized reagents and standards for bioanalytical research - Only one responsible source identified (The University of Liverpool) - No specific product part numbers or quantities provided - Commercial item acquisition under FAR Part 12; sole source justification under FAR Part 6.103-1 - No competing vendors or products listed - No detailed period of performance or contract value disclosed

Description

Procurement Type: Sole Source Simplified Acquisition Procedures (SAP) Purchase Order for Commercial Items

Authority: FAR Part 6.103-1, Only One Responsible Source

Subject: Notice of Intent to Award a Sole Source Contract – Sequencing Bundibugyo virus disease (BDBV) in the 2026 outbreak

Description: The Food and Drug Administration (FDA) intends to award a Sole Source firm-fixed price purchase order to The University of Liverpool for the Sequencing Bundibugyo virus disease (BDBV) in the 2026 outbreak, in accordance with the authority under FAR Part 6.103-1, Only One Responsible Source. This procurement is being conducted under simplified acquisition procedures in accordance with FAR Part 12 (RFO). The NAICS Code for this action is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

The primary objective of this requirement is to obtain critical reagents such as procure reference standards and internal standards to perform bioanalytical method development and sample analysis to determine the quantification of CYP enzyme substrates/metabolites and transporter substrates in hepatocyte experiments.

Responses:

Responses to this notice should be sent to Ryan Alexander at ryan.alexander@fda.hhs.gov by 5:00 pm July 29, 2026. This notice is not a request for competitive quotes. Any other firms desiring consideration must fully identify their interest and capability of meeting the requirements by submitting a capability statement. Any response shall undergo review to determine if it can meet the requirements. A determination by the Government not to compete this proposed requirement based upon a response to this notice is solely within the discretion of the Government.

View original listing